Validea Detailed Fundamental Analysis

Validea's guru fundamental report indicates that AbbVie (ABBV) is a strong candidate based on Partha Mohanram's P/B Growth Investor model, receiving a 77% rating. The model, which favors low book-to-market stocks with sustained growth characteristics, positively assesses AbbVie's book/market ratio, return on assets, cash flow, and sales variance, but flags concerns regarding capital expenditures and research & development relative to assets. Mohanram's research identifies criteria to differentiate successful growth stocks from underperformers using financial statement analysis.

Analysis

Validea's guru fundamental report for AbbVie Inc. (ABBV) indicates a moderately positive assessment based on Partha Mohanram's P/B Growth Investor model, assigning the stock a 77% rating. This model prioritizes low book-to-market stocks exhibiting characteristics indicative of sustained future growth. While a score of 80% or above typically signals strategy interest and 90% strong interest, ABBV's current rating suggests it meets several key criteria, specifically passing tests related to its book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow from operations and return on assets, return on assets variance, sales variance, and advertising to assets. However, the model flagged deficiencies in ABBV's capital expenditures to assets and research and development to assets. Mohanram's underlying academic research, upon which this model is based, focuses on identifying financial statement criteria that differentiate successful growth stocks from those that may underperform, particularly among low book-to-market equities.

Key Decisions for Investors

• Investors employing growth-oriented strategies, particularly those aligned with Partha Mohanram's P/B Growth Investor model, should consider ABBV for further due diligence, noting its 77% score indicates potential but not definitive strength according to this specific strategy.
• A critical area for investigation should be the reasons behind ABBV's failure on the capital expenditure to assets and research and development to assets criteria, as these are significant for a biotechnology company's long-term innovation and growth trajectory.
• Evaluate whether the specific growth characteristics highlighted by the model, alongside the identified weaknesses in investment metrics, align with individual portfolio risk parameters and return objectives for a large-cap stock in the Biotechnology & Drugs industry.